{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:49:30Z","timestamp":1773971370476,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016105","name":"Project on Maternal and Child Health Talents of Jiangsu Province","doi-asserted-by":"publisher","award":["FYX202410"],"award-info":[{"award-number":["FYX202410"]}],"id":[{"id":"10.13039\/100016105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018557","name":"Science and Technology Project of Nantong City","doi-asserted-by":"publisher","award":["MSZ2023044"],"award-info":[{"award-number":["MSZ2023044"]}],"id":[{"id":"10.13039\/501100018557","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.tice.2025.103304","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T07:38:38Z","timestamp":1767080318000},"page":"103304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Smad7 drives cisplatin resistance in ovarian cancer via a PRMT5-dependent mechanism"],"prefix":"10.1016","volume":"99","author":[{"given":"Jinlong","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geshuyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manman","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tice.2025.103304_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.tice.2025.103304_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.JAA.0000000000000042","article-title":"Ovarian cancer: a review for primary care providers","volume":"37","author":"Thull","year":"2024","journal-title":"Jaapa"},{"issue":"12","key":"10.1016\/j.tice.2025.103304_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126532","article-title":"Ovarian cancer immunotherapy and personalized medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.tice.2025.103304_bib4","doi-asserted-by":"crossref","DOI":"10.3892\/or.2024.8705","article-title":"Advances in artificial intelligence for the diagnosis and treatment of ovarian cancer (Review)","volume":"51","author":"Wang","year":"2024","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.tice.2025.103304_bib5","doi-asserted-by":"crossref","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.tice.2025.103304_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tice.2025.103304_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114205","article-title":"Therapeutic strategies to overcome cisplatin resistance in ovarian cancer","volume":"232","author":"Song","year":"2022","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.tice.2025.103304_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122720","article-title":"Targeting ferroptosis in ovarian cancer: novel strategies to overcome chemotherapy resistance","volume":"349","author":"Kapper","year":"2024","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.tice.2025.103304_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010070","article-title":"Mithramycin and analogs for overcoming cisplatin resistance in ovarian cancer","volume":"9","author":"Schweer","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.tice.2025.103304_bib10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s12276-021-00613-y","article-title":"Protein arginine methyltransferases: promising targets for cancer therapy","volume":"53","author":"Hwang","year":"2021","journal-title":"Exp. Mol. Med"},{"issue":"9","key":"10.1016\/j.tice.2025.103304_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41419-023-06149-5","article-title":"Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.tice.2025.103304_bib12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.celrep.2019.12.061","article-title":"PRMT1 Is recruited via DNA-PK to chromatin where it sustains the senescence-associated secretory phenotype in response to cisplatin","volume":"30","author":"Musiani","year":"2020","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.tice.2025.103304_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1369\/0022155413475452","article-title":"Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer","volume":"61","author":"Bao","year":"2013","journal-title":"J. Histochem Cytochem"},{"issue":"1","key":"10.1016\/j.tice.2025.103304_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1186\/s12885-023-11260-z","article-title":"Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer","volume":"23","author":"O'Brien","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.tice.2025.103304_bib15","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/s41467-022-31645-1","article-title":"PRMT5 activates AKT via methylation to promote tumor metastasis","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tice.2025.103304_bib16","series-title":"Copyright \u00a9 2011, National Academy of Sciences.: Washington (DC)","article-title":"The National Academies Collection: Reports funded by National Institutes of Health, in Guide for the Care and Use of Laboratory Animals","year":"2011"},{"issue":"8","key":"10.1016\/j.tice.2025.103304_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"issue":"2","key":"10.1016\/j.tice.2025.103304_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.245","article-title":"PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1","volume":"4","author":"Xie","year":"2023","journal-title":"MedComm"},{"issue":"6","key":"10.1016\/j.tice.2025.103304_bib19","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1086\/302173","article-title":"The tumor-suppressor function of E-cadherin","volume":"63","author":"Semb","year":"1998","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.tice.2025.103304_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1196\/annals.1294.016","article-title":"Cadherin switch in tumor progression","volume":"1014","author":"Hazan","year":"2004","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"10","key":"10.1016\/j.tice.2025.103304_bib21","article-title":"Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances","volume":"18","author":"Huang","year":"2018","journal-title":"Sens. (Basel)"},{"issue":"94","key":"10.1016\/j.tice.2025.103304_bib22","doi-asserted-by":"crossref","first-page":"36705","DOI":"10.18632\/oncotarget.26404","article-title":"Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer","volume":"9","author":"Shailesh","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.tice.2025.103304_bib23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/01.bor.0000137893.68929.86","article-title":"Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches","volume":"16","author":"Christner","year":"2004","journal-title":"Curr. Opin. Rheuma"},{"issue":"9","key":"10.1016\/j.tice.2025.103304_bib24","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.1007\/s13277-014-2203-7","article-title":"SMAD7: a timer of tumor progression targeting TGF-\u03b2 signaling","volume":"35","author":"Luo","year":"2014","journal-title":"Tumour Biol."},{"issue":"11","key":"10.1016\/j.tice.2025.103304_bib25","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.tice.2025.103304_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/onc.2016.205","article-title":"A TGF\u03b2-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.tice.2025.103304_bib27","first-page":"2003047","article-title":"PRMT5 enables robust STAT3 activation via arginine symmetric dimethylation of SMAD7","volume":"8","author":"Cai","year":"2021","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.tice.2025.103304_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J. Hematol. Oncol."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625005865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625005865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:32:31Z","timestamp":1773966751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816625005865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"alternative-id":["S0040816625005865"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2025.103304","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Smad7 drives cisplatin resistance in ovarian cancer via a PRMT5-dependent mechanism","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2025.103304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103304"}}